Cargando…

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment

A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and human monoclonal antibodies (mAb) against the EBOV GP have shown promise in animals and human...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cross, Robert W., Bornholdt, Zachary A., Prasad, Abhishek N., Geisbert, Joan B., Borisevich, Viktoriya, Agans, Krystle N., Deer, Daniel J., Melody, Kevin, Fenton, Karla A., Feldmann, Heinz, Sprecher, Armand, Zeitlin, Larry, Geisbert, Thomas W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385100/ https://www.ncbi.nlm.nih.gov/pubmed/32719371 http://dx.doi.org/10.1038/s41467-020-17446-4

Ejemplares similares

A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease
por: Foster, Stephanie L., et al.
Publicado: (2022)

Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates
por: Woolsey, Courtney, et al.
Publicado: (2018)

Immune correlates of postexposure vaccine protection against Marburg virus
por: Woolsey, Courtney, et al.
Publicado: (2020)

Crimean-Congo hemorrhagic fever virus strains Hoti and Afghanistan cause viremia and mild clinical disease in cynomolgus monkeys
por: Cross, Robert W., et al.
Publicado: (2020)

Bundibugyo ebolavirus Survival Is Associated with Early Activation of Adaptive Immunity and Reduced Myeloid-Derived Suppressor Cell Signaling
por: Woolsey, Courtney, et al.
Publicado: (2021)

Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase
por: Cross, Robert W, et al.
Publicado: (2020)

Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase
por: Cross, Robert W., et al.
Publicado: (2020)

Use of convalescent serum reduces severity of COVID-19 in nonhuman primates
por: Cross, Robert W., et al.
Publicado: (2021)

Postexposure Prophylaxis With rVSV-ZEBOV Following Exposure to a Patient With Ebola Virus Disease Relapse in the United Kingdom: An Operational, Safety, and Immunogenicity Report
por: Davis, Chris, et al.
Publicado: (2019)

Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo)
por: Cross, Robert W, et al.
Publicado: (2018)

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization()
por: Dahlke, Christine, et al.
Publicado: (2017)

Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
por: Sorvillo, Teresa E., et al.
Publicado: (2021)

From discovery to delivery: public sector development of the rVSV-ZEBOV Ebola vaccine
por: Herder, Matthew, et al.
Publicado: (2020)

An Intranasal Exposure Model of Lethal Nipah Virus Infection in African Green Monkeys
por: Geisbert, Joan B, et al.
Publicado: (2020)

Natural history of Sudan ebolavirus infection in rhesus and cynomolgus macaques
por: Woolsey, Courtney, et al.
Publicado: (2022)

Combination therapy protects macaques against advanced Marburg virus disease
por: Cross, Robert W., et al.
Publicado: (2021)

Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus
por: Mire, Chad E., et al.
Publicado: (2016)

Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease
por: Cross, Robert W., et al.
Publicado: (2022)

Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine
por: Farooq, Fouzia, et al.
Publicado: (2016)

A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge
por: Woolsey, Courtney, et al.
Publicado: (2022)

Establishment of an African green monkey model for COVID-19
por: Woolsey, Courtney, et al.
Publicado: (2020)

Establishment of an African green monkey model for COVID-19 and protection against reinfection
por: Woolsey, Courtney, et al.
Publicado: (2020)

Recombinant vesicular stomatitis virus–vectored vaccine induces long-lasting immunity against Nipah virus disease
por: Woolsey, Courtney, et al.
Publicado: (2023)

Natural history of nonhuman primates after conjunctival exposure to Ebola virus
por: Cross, Robert W., et al.
Publicado: (2023)

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV
por: Azizi, Hiva, et al.
Publicado: (2023)

Postexposure Treatment of Marburg Virus Infection
por: Geisbert, Thomas W., et al.
Publicado: (2010)

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
por: Hoff, Nicole A., et al.
Publicado: (2022)

Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy
por: Mire, Chad E., et al.
Publicado: (2016)

A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
por: Geisbert, Thomas W., et al.
Publicado: (2021)

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
por: Rechtien, Anne, et al.
Publicado: (2017)

Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic
por: Kuang, Erin, et al.
Publicado: (2022)

The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus
por: Cross, Robert W., et al.
Publicado: (2016)

A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus
por: Cross, Robert W., et al.
Publicado: (2023)

Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
por: Pejoski, David, et al.
Publicado: (2020)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
por: Tell, Joan G., et al.
Publicado: (2020)

Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody
por: Zeitlin, Larry, et al.
Publicado: (2021)

Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease
por: Mire, Chad E., et al.
Publicado: (2019)

Antagonism of STAT1 by Nipah virus P gene products modulates disease course but not lethal outcome in the ferret model
por: Satterfield, Benjamin A., et al.
Publicado: (2019)

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report
por: Gsell, Pierre-Stéphane, et al.
Publicado: (2017)

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
por: Agnandji, Selidji T., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qvoldj9p6rtbcno4s9n2ga7ckd